Tumour Lymphocytic Infiltration, Its Structure and Influence in Colorectal Cancer Progression by Trajkovski, Gjorgji et al.
 
Open Access Maced J Med Sci electronic publication ahead of print,  
published on June 18, 2018 as https://doi.org/10.3889/oamjms.2018.279 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                          1 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 
https://doi.org/10.3889/oamjms.2018.279 
eISSN: 1857-9655 
Basic Science 
 
 
  
 
Tumour Lymphocytic Infiltration, Its Structure and Influence in 
Colorectal Cancer Progression 
 
 
Gjorgji Trajkovski
1*
, Ljubomir Ognjenovic
1
, Gjorgji Jota
1
, Dragan Hadzi-Manchev
1
, Vanja Trajkovska
3
, Goce Volcevski
1
, 
Dafina Nikolova
4
, Gordana Petrushevska
2
, Vesna Janevska
2
, Vlado Janevski
1
 
 
1
University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic 
of Macedonia; 
2
Institute of Pathology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of 
Macedonia; 
3
University Clinic of TOARILUC, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, 
Republic of Macedonia; 
4
University Clinic of Gastroenterohepatology, Faculty of Medicine, Ss Cyril and Methodius University 
of Skopje, Skopje, Republic of Macedonia 
 
Citation: Trajkovski G, Ognjenovic L, Jota G, Hadzi-
Manchev D, Trajkovska V, Volcevski G, Nikolova D, 
Petrushevska G, Janevska V, Janevski V. Tumour 
Lymphocytic Infiltration, Its Structure and Influence in 
Colorectal Cancer Progression. Open Access Maced J 
Med Sci. https://doi.org/10.3889/oamjms.2018.279 
Keywords: colorectal cancer; tumour-associated 
lymphocytes; grade; stage; immunohistochemistry 
*Correspondence: Gjorgji Trajkovski, MD. University 
Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril 
and Methodius University of Skopje, Skopje, Republic of 
Macedonia. E-mail: trajkovski.77@gmail.com 
Received: 15-May-2018; Revised: 12-Jun-2018; 
Accepted: 14-Jun-2018; Online first: 18-Jun-2018  
Copyright: © 2018 Gjorgji Trajkovski, Ljubomir 
Ognjenovic, Gjorgji Jota, Dragan Hadzi-Manchev, Vanja 
Trajkovska, Goce Volcevski, Dafina Nikolova, Gordana 
Petrushevska, Vesna Janevska, Vlado Janevski. This is 
an open-access article distributed under the terms of the 
Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
Abstract 
BACKGROUND: The role of the immune system in the control of tumour progression has been stressed, 
recently. Many studies indicate the fact that the immune system can prevent tumour progression in several types 
of human malignant neoplasms including colorectal cancer. According to some authors, a higher density of 
“tumour-associated lymphocytes” (TAL), in malignant neoplasms, correlate with prolonged survival of patients. 
AIM: This study aims to determine the structure and the influence of the immune cells, TAL, in the progression of 
colorectal cancer (CRC).  
PATIENTS AND METHODS: The study included 103 patients with CRC operated at the University Clinic of 
Digestive Surgery in Skopje, whose operative material was analysed at the Institute of Pathology, Medical Faculty 
in Skopje. The structure of tumor-associated cells and their density were determined and were correlated with 
neoplasm’s grade, local growth (T), positive lymph nodes, lymphatic invasion and stage of the disease. 
RESULTS: CD4+, CD8+ and CD20+ lymphocytes (Ly) were found in TAL. The density of TAL was significantly 
different in neoplasms with different T status, lymphatic invasion, patients with and without nodal metastasis and 
patients with a different stage of the disease. The density of CD4+, CD8+, and CD20+ cells were significantly 
different in neoplasms with different T. The density of CD8+ and CD20+ lymphocytes was lower in patients with 
nodal metastasis and higher stage.  
CONCLUSION: The density of tumor-associated lymphocytes can anticipate the disease progression in patients 
with colorectal cancer, and the density of TAL influences the control of tumour progression. 
 
 
 
 
 
 
 
 
Introduction 
 
Colorectal cancer (CRC) is the third most 
common malignant disease in the humans, with 
570,000 new cases in the world each year. It is the 
second most common cause for the lethal outcome of 
malignancies in the West European countries and 
eighth in the developing countries. Despite the new 
surgical techniques and treatment with neoadjuvant 
and adjuvant chemotherapy, colorectal cancer is the 
most common tumour of the gastrointestinal tract 
which incidence and mortality continually increase [1] 
[2]. Prognosis of colorectal cancer mostly depends on 
the stage of disease (local growth, positive lymph 
nodes and distant metastasis-TNM classification) and 
depends on many other factors such as 
lymphovascular invasion, histological grade, positive 
surgical margins, preoperative serum values of 
carcinoembryonic antigen (CEA) bowel obstruction 
and many others [3] [4] [5] [6].
 
It is considered that 
new biomarkers such as APC, K-ras, DDS, p53, 
BRAF, TGF- β, CIMP and others can give more 
pieces of information for disease progression. The 
finding that some patients with certain mutations 
(KRAS), who have metastatic disease, do not respond 
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to the treatment with monoclonal antibodies 
represents the basis in the efforts for discovering 
personalised therapies [7] [8] [9] [10] [11]. This is a 
motivation for continued investigation of new 
prognostic factors to determine the disease 
progression and patient outcome as well as to 
improve the knowledge for developing new therapies. 
The role of the immune system in the control of 
disease progression is the basis for the development 
of immunotherapy in patients with malignant diseases 
and is a current topic for research in the field of 
oncology [9] [10] [11]. 
The idea that the immune system can 
recognise a neoplasm was introduced by Paul Ehrlich 
and was supported by Lewis Thomas and Macfarlane 
Burnet. Over the course of time, this idea was turned 
into a concept in which it is considered that the 
immune cells are capable of eliminating malignant 
cells. This is how the theory for “immune surveillance” 
was born. This theory supports hypotheses that the 
immune system is capable of surveillance of the newly 
appeared malignant cells and their elimination [12] 
[13] [14] [15] [16]. 
It is well known that colorectal cancer 
progression is influenced by inter-reaction between 
cancer cells and tumour microenvironment belonging 
to the patient [12] [13] [14]. 
It is considered that the immune cells present 
in tumour-associated stroma are in correlation with 
tumour progression and patient outcome. According to 
some authors, the high density of memory T-cells and 
cytotoxic T-cells in malignant neoplasms (tumour-
associated lymphocytes-TAL) is in correlation with 
prolonged survival of patients [17] [18] [19]. 
Analysis of stromal inflammatory infiltrate, and 
tumour-infiltrating lymphocytes in CRC has not 
attracted the attention of researchers in the Republic 
of Macedonia recently, but new therapeutic 
approaches in the treatment of patients with CRC 
need new basic investigations to provide better 
management of these patients. According to that, we 
aimed to determine the density of TAL, the type of 
some immune cells, “tumour-associated 
lymphocytes”, and their influence on CRC 
progression. 
 
 
Material and Methods 
 
The study included 103 patients with CRC, 68 
(66.2%) male, and 35 (33.98%) female with the age of 
the patients ranged from 33 to 97 years, the mean 
age 64.57 ± 11.5 years. All of them underwent surgery 
in our institution, and their operative material was 
routinely analysed for histopathological diagnosis and 
pTNM staging at the Institute of Pathology and was 
additionally analysed for TAL. 
In this study the following parameters were 
examined: localisation of a tumour, local growth (T 
status), and grade of tumour differentiation (G), the 
presence of positive lymph nodes (LN) as well as the 
stage and the density of TAL. 
The type of TAL was defined by 
immunohistochemical staining with antibodies against 
CD4 (Dako Monoclonal Mouse Anti-Human CD4, 
Clone 4B12); CD8 (Dako Monoclonal Mouse Anti-
Human CD8, Clone C8/144B); CD20 (Dako 
Monoclonal Mouse Anti-Human CD20, Clone L26); 
with a standard procedure using Immunoperoxidase 
LSAB + system. 
The density of TAL was determined 
semiquantitatively. The density of all cells (TAL) was 
determined in the first step in 4 grades and the density 
of positively stained cells from the total number of TAL 
for each marker individually was determined in the 
second step in the same manner as absent (-), scanty 
(+), moderate (++) and abundant (+++). To confirm 
consistency of grading, the cases were scored 
independently by two investigators. Examples of 
grading TAL and immune cell staining and their 
grading are shown in Figure 1. 
  
  
  
Figure 1: a) Scanty (+) Ly infiltration in the tumor invasive front 
(HEx40) b) Abundant (+++) Ly infiltration in the tumor invasive front 
(Hex40) c) Moderate (++) CD4 Ly infiltration (x40) d) Abundant 
CD4+ Ly infiltration (x40) e) Higher magnification of CD4+ cells 
(x200) f) Higher magnification of CD20+ cells in the tumor invasive 
front of CRC (x200) 
 
Statistical analysis 
Descriptive statistical methods were used for 
Trajkovski et al. Tumor Lymphocytic Infiltration, Its Structure and Influence in Colorectal Cancer Progression 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
statistical analysis of the data. Categorical variables 
are presented with absolute and relative numbers (%). 
Fisher’s exact test was used for comparison of 
categorical variables. Spearman’s correlation 
coefficient was used to determine the degree of 
correlation between analysed parameters. The 
statistical program SPSS for Windows, version 19.0 
was used. 
 
 
Results 
 
Density of TAL 
Distribution of patients and density of TAL 
according to the localisation of a tumour are shown in 
Table 1.  
Table 1: Distribution of patients and density of TAL according 
to the cancer localisation 
Localization Quantity of TAL 
 No of patients Scanty 
(No = 59) 
Moderate 
(No = 32) 
Abundant 
(No = 12) 
Coecum 12 (11.65%) 8 (66.67) 3 (25) 1 (8.33) 
Colon asc 9 (8.74%) 6 (66.67) 3 (33.33) 0 
Flex hepat 3 (2.91%) 1 (33.330 2 (66.67) 0 
Colon trans 5 (4.85%) 2 (40) 2 (40) 1 (20) 
Flex lienlis 3 (2.91%) 2 (66.67) 1 (33.33) 0 
Colon des 3 (2.91%) 3 (100) 0 0 
Sigma 29 (28.16%) 17 (58.62) 7 (24.14) 5 (17.24) 
Rectosig 8 (7.77%) 5 (62.5) 2 (25) 1 (12.5) 
Rectum 31 (30.09%) 15 (48.39) 12 (38.71) 4 (12.9) 
 
Stage of the disease and local growth of 
CRC, i.e. T category according to the TNM 
classification for colorectal cancer (AJCC, 2010), 
number of patients with negative and positive lymph 
nodes, number of cases with and without lymphatic 
invasion, and the grade of differentiation in the 
analysed series are illustrated in Table 2. The largest 
number of examined patients was with a tumour in T3 
and T4 local growth without metastatic deposits in the 
local lymph nodes, without lymphatic invasion and 
with moderately differentiated neoplasms. The density 
of tumor-associated lymphocytes about the 
parameters mentioned above is presented in the 
same Table. 
Table 2: Density of TAL according to the stage of disease, T 
category and nodal status and lymphatic invasion  
Stage Quantity (Density) of TAL P-value 
 No of 
patients 
Scanty Moderate Abundant  
I 11 1 (9.09) 5 (45.45) 5 (45.45) <0.0001** 
II 45 15 (35.71) 23 (22.33) 7 (16.67) 
III 41 37 (35.92) 4 (9.09) 0 
IV 6 3 (50) 3 (50) 0 
T category      
1 5 0 4 (80) 1 (20) 0.0018** 
2 7 1 (14.29) 2 (28.57) 4 (57.14) 
3 60 35 (58.33) 20 (33.33) 5 (8.33) 
4 31 23 (74.19) 6 (19.35) 2 (6.45) 
N category      
N0 56 17 (30.36) 27 (48.21) 12 (21.43) 0.0001** 
N1/N2 47 42 (89.36) 5 (10.64) 0 
L category      
L0 54 20 (37.04) 26 (48.15) 8 (14.81) 0.00005** 
L1 49 39 (79.59) 6 (12.24) 4 (8.16) 
P (Kruskal-Wallis test) *P < 0.05; **P < 0.01. 
 
The density of TAL was higher in patients with 
lower stage I and II of the disease, in tumours with 
less local invasion, in patients without nodal 
metastasis, and in tumours with no lymphatic 
invasion. On the contrary, in stage III and IV of the 
disease, the density of TAL was low in the most of the 
analysed cases and the tumour infiltrating 
lymphocytes was scanty in patients with advanced 
local growth, with nodal metastasis and with lymphatic 
invasion. 
Statistical analysis did not show statistical 
differentiation in the quantity of TAL according to 
tumour differentiation (P > 0.05).  
 
Different cell types of TAL and their 
density in CRC 
CD20, CD4 and CD8 positive cells in different quantity 
were found in all analysed cases. 
 
CD20+ Lymphocytes  
The density of CD20+ tumour-associated 
lymphocytes about the stage of disease, T and N 
category, and lymphatic invasion is presented in Table 
3. 
Table 3: Density of CD20+ cells according to the tumour stage, 
T and N category, and lymphatic invasion  
Stage  The quantity of CD20+ Ly P-value 
 N
o
 of 
patients 
CD20+ Ly 
not present 
Scanty Moderate Abundant  
I 11 0 0 6 (54.55) 5 (45.45) <0.0001** 
II 45 1 (2.38) 24 (23.30) 16 (38.1) 4 (9.52) 
III 41 0 36 (34.95) 4 (9.09) 1 (2.27) 
IV 6 0 6 (100) 0 0 
T category       
1 5 0 0 3 (60) 2 (40) 0.0002** 
2 7 0 0 4 (57.14) 3 (42.86) 
3 60 1 (1.67) 41 (68.33) 13 (21.67) 5 (8.33) 
4 31 0 25 (80.65) 6 (19.35) 0 
N category       
N0 56 1 (1.79) 25 (44.64) 21 (37.5) 9 (16.07) <0.0001** 
N1/N2 47 0 41 (87.23) 5 (10.64) 1 (2.13) 
L category       
L0 54 1 (1.85) 26 (48.15) 18 (33.33) 9 (16.67) 0.001** 
L1 49 0 40 (81.63) 8 (16.33) 1 (2.04) 
P (Kruskal-Wallis test) *P < 0.05; **P < 0.01. 
 
We found a significant difference in the 
density of CD20+ lymphocyte (Ly) in all analysed 
parameters.  
Scanty CD20+ Ly infiltrates found in patients 
with advanced local growth, with nodal metastases, 
lymphatic invasion and with a higher stage of the 
disease (100% Stage IV, 88.64% Stage III, 50% 
Stage II and 0% of patients in Stage I). The density of 
CD20+ Ly infiltrate lower (scanty) in patients with 
poorly differentiated tumours but without a statistically 
significant difference (P = 0.089).  
  
CD4+ Lymphocytes 
The density of CD4+ tumour-associated 
lymphocytes about the stage of disease, T and N 
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category, and lymphatic invasion is presented in Table 
4. 
Table 4: Density of CD4+ tumour-associated lymphocytes 
about the stage of disease, T and N category, and lymphatic 
invasion  
Stage The quantity of CD4+ Lymphocytes P-value 
 No of patients Scanty Moderate Abundant  
I 11 0 10 (90.91) 1 (9.09) P = 0.11 ns 
II 45 10 (23.81) 26 (25.24) 9 (21.43) 
III 41 4 (9.09) 34 (33.00) 3 (6.82) 
IV 6 0 6 (100) 0 
T category      
1 5 0 4 (80) 1 (20) P = 0.034* 
2 7 0 7 (100) 0 
3 60 6 (10) 46 (76.67) 8 (13.33) 
4 31 8 (25.81) 19 (61.29) 4 (12.9) 
N category      
N0 56 10 (17.86) 36 (64.29) 10 (17.86) P = 0.055 ns 
N1/N2 47 4 (8.51) 40 (85.11) 3 (6.38) 
L category      
L0 54 11 (20.37) 37 (68.52) 6 (11.11) P = 0.11 ns 
L1 49 3 (6.12) 39 (79.59) 7 (14.29) 
P (Kruskal-Wallis test) *P < 0.05; **P < 0.01. 
 
The low density of CD4+ Ly was detected in 
100% of tumours with advanced local tumour growth 
(T4 category) and on contrary CD4+ low Ly density 
was not detected in tumours with T1. The statistical 
analysis confirmed that the density of CD4+ 
lymphocytes in the infiltrative front of a tumour 
significantly depended on the local growth of the 
disease. 
Patients with regional lymph nodes 
metastasis had a lower density of CD4+ Ly infiltrate 
than patients without metastasis, but there was no a 
statistically significant difference in the density of 
CD4+ Ly according to the presence of lymph nodes 
metastasis. No statistical significance was found in the 
density of CD4+ Ly infiltrate according to the Stage, 
lymphatic invasion and grade also. 
 
CD8 Lymphocytes  
The density of CD8+ tumour-associated 
lymphocytes about the stage of disease, T and N 
category, and lymphatic invasion is presented in Table 
5. 
Table 5: Density of CD8+ tumour-associated lymphocytes 
about the stage of disease, T and N category, and lymphatic 
invasion  
Stage  The quantity of CD8+ Lymphocytes p-value 
 No of 
patients 
CD8+ Ly 
not present 
scanty moderate abundant  
I 11 0 0 11 (100) 0 0.0055** 
II 45 1 (2.38) 12 (28.57) 28 (66.67) 1 (2.38) 
III 41 0 24 (54.55) 20 (45.45) 0 
IV 6 0 3 (50) 3 (50) 0 
T category       
1 5 0 0 5 (100) 0 0.006** 
2 7 0 0 7 (100) 0 
3 60 1 (1.67) 22 (36.67) 37 (61.67) 0 
4 31 0 17 (54.84) 13 (41.94) 1 (3.23) 
N category       
N0 56 1 (1.79) 15 (26.79) 39 (69.64) 1 (1.79) 0.024* 
N1/N2 47 0 24 (51.06) 23 (48.94) 0 
L category       
L0 54 0 18 (33.33) 35 (64.81) 1 (1.85) 0.36 ns 
L1 49 1 (2.04) 21 (42.86) 27 (55.1) 0 
P (Kruskal-Wallis test) *P < 0.05; **P < 0.01. 
 
We found a significant difference in the 
quantity of CD8+ Ly in all analysed parameters except 
lymphatic invasion.  
The density of CD8+ Ly significantly differs 
according to the local tumour growth. The low density 
of CD8+ Ly infiltrate significantly more often was 
present in patients with T4 and T3 status (54.84%, 
36.67% respectively); there were no patients with T1 
and T2 with a low density of CD8+ Ly infiltrate.  
The density of CD8+ Ly was significantly 
lower in patients with nodal metastasis, lymphatic 
invasion and with an advanced stage of the disease.  
We did not find a statistical difference in the 
density of CD8+ Ly according to the histological 
differentiation of a tumour. 
The moderate density of CD8+ lymphocytes 
decreased when the grade of the differentiation 
decreased, but the difference was not significant. 
 
Correlations 
The correlations of the density of tumour-
associated lymphocytes with T tumour status, the 
involvement of the regional lymph nodes, lymphatic 
invasion, stage and the grade of differentiation were 
done using the Spearman’s correlation test. 
Correlations were determined between the different T 
cell types also.  
The results showed a significant negative 
correlation between the density of CD20+ Ly and T 
status, stage and G, i.e. the density of CD20+ Ly was 
lower in less differentiated tumours with advanced 
local growth and higher stage. The density of CD20+ 
Ly was in positive correlation with the density of CD8+ 
Ly and the density of TAL (Table 6).  
The density of CD8+ Ly was lower in tumours 
with advanced local growth and higher stage of the 
disease. Correlations were not statistically significant 
except for the density of CD8+ Ly and the stage of the 
disease (Table 6).  
Table 6: Correlations of the quantity of TAL and all other 
analysed parameters  
CD20 Spearman R t-test, P-level 
CD20 / CD8 0.367 3.97, P = 0.00013** 
CD20 / TAL 0.436 4.87, P = 0.000004** 
CD20 / T  -0.407 4.48, P = 0.00002** 
CD20 / Stage  -0.564 6.87, P < 0.0001** 
CD20 / G  -0.220 2.27, P = 0.025* 
CD4   
CD4 / CD 8 0.387 4.21, P = 0.000055** 
CD4 / CD 20 0.016 0.16, P = 0.87 
CD4 / TAL 0.342 3.66, P = 0.00041** 
CD4 / T  -0.155 1.57, P = 0.12 
CD4 / Stage -0.034 0.34, P = 0.74 
CD4 / G  -0.091 0.92, P = 0.36 
CD8   
CD8 / TAL 0.381 4.14, P = 0.000073** 
CD8 / T -0.271 2.83, P = 0.0056** 
CD8 / Stage  -0.324 3.44, P = 0.00084** 
CD8 / G  -0.107 1.08, P = 0.28 
*P < 0.05; **P < 0.01. 
 
Statistically, a significant correlation was 
found between CD4+ Ly and CD8+ Ly and the total 
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amount of TAL (Table 6). The density of CD8+ Ly 
increased when the density of Total amount of TAL 
increased and when the density of CD4+ Ly increased 
(Table 6). There was also a significant positive 
correlation between CD20+ cells and CD8+cells. 
 
 
Discussion 
 
Rudolf Virchow, 150 years ago, was the first 
who described inflammatory cells in tumours and 
established the theory that tumours arise at chronic 
inflammation sites. It is known that the risk of 
developing colorectal cancer is greater in patients with 
ulcerative colitis and those with Crohn’s disease. 
Despite the knowledge that chronic inflammation is a 
risk for development of a malignant neoplasm, many 
clinical and experimental studies stress the protective 
role of immune cells in cancer progression, hence, the 
statements and cognitions that immune response 
plays a key role in fighting tumour growth and its 
dissemination [7]. 
Some authors consider that the type, density 
and location of the immune cells in colorectal cancer 
can be superior and independent prognostic factor for 
tumour progression [7].  
Cancer progression is a complex process that 
is influenced by genetic, epigenetic and environmental 
factors, but at the same time, it is a process of 
interaction between cancer cells and their 
microenvironment, that is, stroma. Tumour stroma is 
built of different cells among which are inflammatory 
cells that belong to congenital and inherited immune 
system [20] [21] [22]. Former investigations have 
shown that lymphocytes that infiltrate the tumour-
tumour infiltrating lymphocytes (TIL/TAL) are 
predominantly T lymphocytes among which two 
subtypes are identified CD4+ and CD8+ T 
lymphocytes. CD4+ T lymphocytes are T helper cells, 
whereas CD8+ T lymphocytes are cytotoxic cells 
capable of killing the “target cell”, i.e. tumour cell 
which exposed antigens CD8+ T lymphocytes are 
capable of recognising. They are able to destroy 
tumor cells in direct cell interaction by releasing lytic 
components [22] [23] [24] [25] [26] [27]. CD4+ T 
lymphocytes are helper cells that regulate their 
proliferation and coordinate the immune response by 
stimulating the other immune cells. They are stratified 
in subgroups T helper 1 (Th1) and T helper 2 (Th2) 
cells. Th1 CD4+ T lymphocytes are responsible for the 
proliferation of cytotoxic T lymphocytes that participate 
in the killing of tumour cells. 
In addition to T lymphocytes, B CD20+ 
lymphocytes arranged in aggregates have been found 
among TAL together with other immune cells. In 
lymph glands and the remaining lymphoid tissue, B 
lymphocytes receive signals for growth, differentiation 
and affinity maturation from follicular T helper immune 
cells. They differentiate into plasma cells and memory 
cells with long lifespan [28]. The process of lymphoid 
neogenesis is described in infectious diseases, 
chronic inflammation processes, autoimmune 
diseases and chronic graft rejection [29] [30] [31]. In 
these conditions, T and B cells cooperate to create a 
strong immune response when B cells enhance T cell 
response by antigen presentation, costimulation and 
modulation of migration and function of dendritic cells 
[28], 29]. 
Lymphoid neogenesis is also described in 
malignant neoplasms, while the role of CD20+ 
lymphocytes in tertiary lymphoid structures that are 
found in these neoplasms has not been completely 
clarified and it is still in the phase of research [29]. 
Nowadays many patients with malignant neoplasms 
develop tumour-specific antibodies, and B cells have 
a significant role in the immune response to neoplasm 
both by exacerbating cancer-associated inflammation 
and by the effect they have on T lymphocytes, 
macrophages and myeloid stem cells. 
We found a statistically significant correlation 
between the examined subtypes of lymphocytes with 
a negative trend between CD4+ and CD20+ cells and 
CD8+, CD20+ cells and also a positive trend between 
CD4+ and CD8+. The correlation implies mutual 
connection in the function of these cells in one 
common immune response to tumour antigens. 
TAL-tumour infiltrating lymphocytes are 
concentrated in the stroma of an invasive tumour 
front. Many authors examined the role of TAL in tumor 
progression in relation to survival of patients with 
colorectal cancer [23] [24] [25] [26] [32] [33]. 
Even though for a long time it was considered 
that colorectal cancer is a bad immunogenic tumor, 
the new cognitions suggest that there is a substantial 
immune response to this disease and that the 
presence of the immune response is connected with a 
better prognosis of patients with colorectal cancer, 
that is, the increased presence of T cytotoxic 
lymphocytes is associated with absence of early 
metastases and absence of early recurrence, as well 
as that the type of density and location of the immune 
cells have prognostic significance in colorectal cancer 
[7] [33] [34].  
Therefore, tumour-associated lymphocytes 
can provide significant prognostic information about 
patients with colorectal cancer, which could be used 
for treatment with adjuvant therapy in a different stage 
of cancer [29]. 
The results from the analysis of TAL in the 
invasive front of cancer in our group of patients with 
colorectal cancer showed the presence of T (CD4+ 
and CD8+) and B (CD20+) lymphocytes and their 
density significantly correlated with clinically-
pathologic parameters for disease progression. The 
density of TAL was higher in patients with lower stage 
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(I and II) of the disease, in tumours with less local 
invasion, in patients without nodal metastasis, and in 
tumours with no lymphatic invasion. The density of 
CD8+ and CD20+ lymphocytes in a neoplasm was 
higher in patients without metastases in lymph nodes 
and with a lower stage of the disease. Lower density 
of CD20+ lymphocytes was found in neoplasms of 
patients with advanced local growth and lymphatic 
tumor invasion. Thus, it can be concluded that the 
density of tumor-associated lymphocytes can be a 
parameter for neoplasm progression in patients with 
colorectal cancer and the density of tumor-associated 
lymphocytes influences the control of tumor 
progression.  
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